Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.

Abstract

Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

• Authors: Lucy J Schmidt, Donald J Tindall
• Journal: The Journal of steroid biochemistry and molecular biology (J Steroid Biochem Mol Biol) Vol. 125 Issue 1-2 Pg. 32-8 (May 2011) ISSN: 1879-1220 [Electronic] England
• PMID: 20883781 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2010 Elsevier Ltd. All rights reserved.

Chemical References

• 5-alpha Reductase Inhibitors
• Azasteroids
• Finasteride
• Dutasteride

Topics

• 5-alpha Reductase Inhibitors (chemistry, therapeutic use)
• Azasteroids (chemistry, therapeutic use)
• Clinical Trials as Topic
• Dutasteride
• Finasteride (chemistry, therapeutic use)
• Humans
• Male
• Molecular Structure
• Prostatic Hyperplasia (drug therapy)
• Prostatic Neoplasms (drug therapy)